Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 13/20 | 0.51 |
| ▸ | KLKB1 | P03952 | 7/20 | 0.50 |
| ▸ | F2 | P00734 | 4/20 | 0.49 |
| ▸ | F9 | P00740 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7071556 | 0.83 | F10 (0.70) | F10F2F9 | |
| SCHEMBL7071551 | 0.83 | F10 (0.58) | F10F2F9 | |
| SCHEMBL1997130 | 0.80 | KLKB1 (0.53) | F10KLKB1F2 | |
| SCHEMBL4586574 | 0.79 | KLKB1 (0.41) | F10KLKB1F2 | |
| SCHEMBL6494562 | 0.79 | F10 (0.61) | F10F2F9 | |
| SCHEMBL27519105 | 0.77 | F10 (0.51) | F10KLKB1F2F9 | |
| SCHEMBL7473794 | 0.77 | F10 (0.67) | F10F2F9 | |
| SCHEMBL7540360 | 0.76 | KMT2A (0.56) | F10KLKB1F9 | |
| SCHEMBL31067479 | 0.74 | KLKB1 (0.54) | F10KLKB1F2F9 | |
| SCHEMBL31067480 | 0.74 | KLKB1 (0.58) | F10KLKB1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6465656-B2 | ACYLATING/ACETYLATING ARYLHYDRAZINE, REACTING HYDROZONOYL HALIDE/SULFATE WITH AMINE BASE TO FORM 1-(3-CYANO)PHENYL-2-(TRIFLUOROACETYL)HYDRAZINE | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-10-15 | — | — | US | disclosed |
| EP-1222172-A1 | SYNTHESIS OF 1,3,5-TRISUBSTITUTED PYRAZOLES AND INTERMEDIATES THEREFORE | Bristol-Myers Squibb Pharma Company (US) | 2002-07-17 | — | — | EP | disclosed |
| US-20020055641-A1 | Synthesis of 1,3,5-trisubstituted pyrazoles | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-09 | — | — | US | disclosed |
| US-6329527-B1 | ACYLATING SUBSTITUTEDARYL HYDRAZINE, FORMING DIPOLAR COMPOUND, CONTACTING DIPOLAROPHILE AND SUBJECTING TO OXIDATION, REMOVING PROTECTING GROUP | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2001-12-11 | — | — | US | disclosed |
| WO-2001029006-A1 | SYNTHESIS OF 1,3,5-TRISUBSTITUTED PYRAZOLES AND INTERMEDIATES THEREFORE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055641-A1 | Synthesis of 1,3,5-trisubstituted pyrazoles | TFPI, SERPINC1, F11 | F10 14/4885KLKB1 277/4885F2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.